Re: Intravenous versus oral busulfan - Perhaps not as different as suggested

Biology of Blood and Marrow Transplantation

Volumn 9, Issue 4, 2003, Pages 282-284

  Slattery, John T ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; CHRONIC MYELOID LEUKEMIA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SAFETY; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; LIVER VENOOCCLUSIVE DISEASE; SURVIVAL TIME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BUSULFAN; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INJECTIONS, INTRAVENOUS;

EID: 0742300045     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2003.50029     Document Type: Letter

References (15)

1. Kashyap A Wingard J Cagnoni P et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality Biol Blood Marrow Transplant 8 2002 493-500
2. Andersson BS Thall PF Madden T et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia Biol Blood Marrow Transplant 8 2002 477-485
3. Andersson BS Kashyap A Gian V et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study Biol Blood Marrow Transplant 8 2002 145-154
4. Andersson BS Madden T Tran HT et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study Biol Blood Marrow Transplant 6 2000 548-554
5. Czerwinski M Gibbs JP Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi Drug Metab Dispos 24 1996 1015-1019
6. Grochow LB. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol 20 1993 18-25
7. Slattery JT Sanders JE Buckner CD et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 16 1995 31-42
8. Dix SP Wingard JR Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 17 1996 225-230
9. Russell JA Tran HT Quinlan D et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes Biol Blood Marrow Transplant 8 2002 468-476
10. Grochow LB. Parenteral busulfan: Is therapeutic monitoring still warranted? Biol Blood Marrow Transplant 8 2002 465-467
11. Gibbs JP Yang J-S Slattery JT. Comparison of human liver and small intestinal glutathione S-transferase catalyzed busulfan conjugation in vitro Drug Metab Disp 26 1998 52-55
12. Slattery JT Clift RA Buckner CD et al. Marrow transplantation for chronic myeloid leukemia. The influence of busulfan levels on the outcome of transplantation Blood 89 1997 3055-3060
13. Radich JP Gooley T Bensinger W et al. Allogenic-related transplantation for CML chronic phase using a targeted busulfan and cytoxan preparative regimen Blood In press.
14. McCune JS Gibbs JP Slattery JT. Plasma concentration monitoring of busulfan. Does it improve clinical outcome? Clin Pharmacokin 39 2000 155-165
15. Gibbs JP Gooley T Corneau B et al. The impact of obesity and disease on busulfan oral clearance in adults Blood 93 1999 4436-4440